Senior Housing News June 12, 2024
An experimental Alzheimer’s drug has received unanimous approval from a Food and Drug Administration advisory panel.
The drug, called donanemab, is made by Eli Lilly and has been shown to have benefits of slowing the progression of cognitive decline in people with early stages of Alzheimer’s.
The drug is given as an infusion and works by helping to remove the amyloid plaque buildups thought to cause Alzheimer’s.
Like some other drugs used to treat Alzheimer’s donanemab has side effects that include brain swelling and bleeding. Three people on the drug during a 76-week study.
People taking the drug saw their cognitive decline delayed by 4.5 to 7.5 months, according to Eli Lilly, as noted in recent reporting...
Today's Sponsors
Today's Sponsor